Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for...

Descripción completa

Detalles Bibliográficos
Autores principales: Brahmer, Julie R, Abu-Sbeih, Hamzah, Ascierto, Paolo Antonio, Brufsky, Jill, Cappelli, Laura C, Cortazar, Frank B, Gerber, David E, Hamad, Lamya, Hansen, Eric, Johnson, Douglas B, Lacouture, Mario E, Masters, Gregory A, Naidoo, Jarushka, Nanni, Michele, Perales, Miguel-Angel, Puzanov, Igor, Santomasso, Bianca D, Shanbhag, Satish P, Sharma, Rajeev, Skondra, Dimitra, Sosman, Jeffrey A, Turner, Michelle, Ernstoff, Marc S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237720/
https://www.ncbi.nlm.nih.gov/pubmed/34172516
http://dx.doi.org/10.1136/jitc-2021-002435
_version_ 1783714771929923584
author Brahmer, Julie R
Abu-Sbeih, Hamzah
Ascierto, Paolo Antonio
Brufsky, Jill
Cappelli, Laura C
Cortazar, Frank B
Gerber, David E
Hamad, Lamya
Hansen, Eric
Johnson, Douglas B
Lacouture, Mario E
Masters, Gregory A
Naidoo, Jarushka
Nanni, Michele
Perales, Miguel-Angel
Puzanov, Igor
Santomasso, Bianca D
Shanbhag, Satish P
Sharma, Rajeev
Skondra, Dimitra
Sosman, Jeffrey A
Turner, Michelle
Ernstoff, Marc S
author_facet Brahmer, Julie R
Abu-Sbeih, Hamzah
Ascierto, Paolo Antonio
Brufsky, Jill
Cappelli, Laura C
Cortazar, Frank B
Gerber, David E
Hamad, Lamya
Hansen, Eric
Johnson, Douglas B
Lacouture, Mario E
Masters, Gregory A
Naidoo, Jarushka
Nanni, Michele
Perales, Miguel-Angel
Puzanov, Igor
Santomasso, Bianca D
Shanbhag, Satish P
Sharma, Rajeev
Skondra, Dimitra
Sosman, Jeffrey A
Turner, Michelle
Ernstoff, Marc S
author_sort Brahmer, Julie R
collection PubMed
description Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.
format Online
Article
Text
id pubmed-8237720
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82377202021-07-09 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events Brahmer, Julie R Abu-Sbeih, Hamzah Ascierto, Paolo Antonio Brufsky, Jill Cappelli, Laura C Cortazar, Frank B Gerber, David E Hamad, Lamya Hansen, Eric Johnson, Douglas B Lacouture, Mario E Masters, Gregory A Naidoo, Jarushka Nanni, Michele Perales, Miguel-Angel Puzanov, Igor Santomasso, Bianca D Shanbhag, Satish P Sharma, Rajeev Skondra, Dimitra Sosman, Jeffrey A Turner, Michelle Ernstoff, Marc S J Immunother Cancer Position Article and Guidelines Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients. BMJ Publishing Group 2021-06-25 /pmc/articles/PMC8237720/ /pubmed/34172516 http://dx.doi.org/10.1136/jitc-2021-002435 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Position Article and Guidelines
Brahmer, Julie R
Abu-Sbeih, Hamzah
Ascierto, Paolo Antonio
Brufsky, Jill
Cappelli, Laura C
Cortazar, Frank B
Gerber, David E
Hamad, Lamya
Hansen, Eric
Johnson, Douglas B
Lacouture, Mario E
Masters, Gregory A
Naidoo, Jarushka
Nanni, Michele
Perales, Miguel-Angel
Puzanov, Igor
Santomasso, Bianca D
Shanbhag, Satish P
Sharma, Rajeev
Skondra, Dimitra
Sosman, Jeffrey A
Turner, Michelle
Ernstoff, Marc S
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
title Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
title_full Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
title_fullStr Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
title_full_unstemmed Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
title_short Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
title_sort society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events
topic Position Article and Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237720/
https://www.ncbi.nlm.nih.gov/pubmed/34172516
http://dx.doi.org/10.1136/jitc-2021-002435
work_keys_str_mv AT brahmerjulier societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT abusbeihhamzah societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT asciertopaoloantonio societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT brufskyjill societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT cappellilaurac societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT cortazarfrankb societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT gerberdavide societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT hamadlamya societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT hanseneric societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT johnsondouglasb societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT lacouturemarioe societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT mastersgregorya societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT naidoojarushka societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT nannimichele societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT peralesmiguelangel societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT puzanovigor societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT santomassobiancad societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT shanbhagsatishp societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT sharmarajeev societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT skondradimitra societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT sosmanjeffreya societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT turnermichelle societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents
AT ernstoffmarcs societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunecheckpointinhibitorrelatedadverseevents

Ejemplares similares